Camlin Fine Sciences Board Approves FY26 Audited Results, Appoints New CFO
Camlin Fine Sciences reported audited financial results for FY26. The company appointed Mr. Pankaj Pandey as CFO effective August 18, 2026. The 33rd AGM is scheduled for August 11, 2026. Consolidated loss after tax for FY26 was ₹3,296.62 lakh.
The appointment of a new CFO and the approval of audited financial results are significant corporate events. The financial results, despite showing a reduced loss, indicate ongoing challenges. The AGM date is also a material piece of information for investors.
The announcement includes the approval of audited financial results and key management changes, which are routine corporate actions. While the results show a reduced loss compared to the previous year, the company still reported a consolidated net loss, preventing a positive sentiment. The appointment of a new CFO is a procedural update.
Camlin Fine Sciences Limited announced the outcome of its Board of Directors meeting held on May 26, 2026. The Board approved the Audited Financial Statements (Consolidated and Standalone) for the year ended March 31, 2026, along with the Audited Financial Results for the quarter and year ended March 31, 2026. The company's statutory auditor, M/s. Kalyaniwalla & Mistry LLP, issued unmodified opinions on these financial statements.
The Board has also approved the appointment of M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditors for the financial year ending March 31, 2027. A significant announcement was the appointment of Mr. Pankaj Pandey as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective August 18, 2026. Upon Mr. Pandey's joining, Mr. Santosh Parab will be redesignated as President – Strategy and Global CFO.
Furthermore, the 33rd Annual General Meeting (AGM) of the Company is scheduled to be held on Tuesday, August 11, 2026, at 10:00 a.m. The company's financial results indicated a consolidated loss after tax of ₹3,296.62 lakh for the year ended March 31, 2026, compared to a loss of ₹7,631.05 lakh in the previous year. Standalone net loss after tax for the year ended March 31, 2026, was ₹564.95 lakh, a significant improvement from a loss of ₹1,299.66 lakh in the prior year.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.